Barron's lists a USD 1.58 target for Canopy Growth stock
Published on 10/24/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Barron's listed an average USD 1.58 target from eight ratings on October 8, 2026.
- Canopy Growth is scheduled to publish second-quarter fiscal 2027 results on November 6, 2026.
- Canopy Growth stock costs EUR 0.60 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
- First-quarter fiscal 2027 net revenue grew 13.00 percent, while Canada medical revenue rose 22.00 percent.
Canopy Growth (ISIN CA1380357048) had an average USD 1.58 price target across eight ratings in the Barron's overview dated October 8, 2026. The target gives investors a clear valuation reference in US dollars, while the next company report is scheduled for November 6, 2026. Canopy Growth was trading at EUR 0.60 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Target and reporting date
The Barron's overview listed eight ratings, with an average target of USD 1.58 and a consensus score of Hold on October 8, 2026. Its high target was USD 3.59 and its low target was USD 1.00, showing a wide spread across the published views.
Financial Times reported on October 22, 2026 that Canopy Growth will release second-quarter fiscal 2027 results before US markets open on November 6, 2026. The company also plans an audio webcast at 10:00 a.m. ET on the same date.
Revenue growth sets the operating marker
Canopy Growth's investor page identifies the August 7, 2026 first-quarter fiscal 2027 release as its most recent earnings update. According to Canopy Growth, net revenue grew 13.00 percent in that period. Canada medical cannabis revenue increased 22.00 percent, while international cannabis revenue rose 10.00 percent.
The figures give the November report a specific test: investors will be able to compare second-quarter revenue with the 13.00 percent first-quarter growth rate and assess whether the 22.00 percent Canada medical increase continued. Canopy Growth describes its business as spanning medical and adult-use cannabis, with operations connected to Canada, Germany and the United States.
Nasdaq quote and company scale
On the Nasdaq, Canopy Growth was last at USD 0.68 on October 23, 2026 at 4:00 p.m. ET. The same market snapshot lists a market capitalization of USD 285.9 million, volume of 1,858,045 shares and a trailing P/E ratio of minus 1.42. These figures describe the US listing separately from the euro quotation used for German-market investors.
What November 6 could clarify
The scheduled release will cover the quarter ended September 30, 2026. The company said its balance sheet had been strengthened and that debt maturities had been extended to 2031, making revenue quality and profitability the central points for the next update.
Price remains the daily reference
The euro quotation stood at EUR 0.60 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST. The next company report and the USD 1.58 average target provide the two dated reference points for interpreting the stock's next move.
The further course of trading is shown by the continuously updated real-time quote of Canopy Growth stock.
Canopy Growth stock facts
- Company: Canopy Growth Corporation
- ISIN: CA1380357048
- Ticker: CGC
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 24, 2026, 1:04 p.m. CEST): EUR 0.60
- Market capitalization: USD 285.9 million (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 6, 2026
Market context: Market report Nasdaq Composite.
